Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-09-14
1998-06-09
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3827, C07K 1461
Patent
active
057633940
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention is directed to pharmaceutical formulations containing human growth hormone (hGH) and to methods for making and using such formulations. More particularly, this invention relates to such pharmaceutical formulations having increased stability in aqueous formulation.
BACKGROUND OF THE INVENTION
Human growth hormone formulations known in the art are all lyophilized preparations requiring reconstitution. Per vial, Protropin.RTM. hGH consists of 5 mg hGH, 40 mg mannitol, 0.1 mg monobasic sodium phosphate, 1.6 mg dibasic sodium phosphate, reconstituted to pH 7.8 (Physician's Desk Reference, Medical Economics Co., Orawell, N.J., p. 1049, 1992). Per vial, Humatrope.RTM. hGH consists of 5 mg hGH, 25 mg mannitol, 5 mg glycine, 1.13 mg dibasic sodium phosphate, reconstituted to pH 7.5 (Physician's Desk Reference, p. 1266, 1992).
For a general review for growth hormone formulations, see Pearlman et al., Current Communications in Molecular Biology, eds. D. Marshak and D. Liu, pp. 23-30, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. Other publications of interest regarding stabilization of proteins are as follows.
U.S. Pat. No. 4,297,344 discloses stabilization of coagulation factors II and VIII, antithrombin III, and plasminogen against heat by adding selected amino acids such as glycine, alanine, hydroxyproline, glutamine, and aminobutyric acid, and a carbohydrate such as a monosaccharide, an oligosaccharide, or a sugar alcohol.
U.S. Pat. No. 4,783,441 discloses a method for the prevention of denaturation of proteins such as insulin in aqueous solution at interfaces by the addition of up to 500 ppm surface-active substances comprising a chain of alternating, weakly hydrophilic and weakly hydrophobic zones at pH 6.8-8.0.
U.S. Pat. No. 4,812,557 discloses a method of stabilization of interleukin-2 using human serum albumin.
European Patent Application Publication No. 0 303 746 discloses stabilization of growth promoting hormones with polyols consisting of non-reducing sugars, sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans, and Ficoll, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts.
European Patent Application Publication No. 0 211 601 discloses the stabilization of growth promoting hormones in a gel matrix formed by a block copolymer containing polyoxyethylene-polyoxypropylene units and having an average molecular weight of about 1,100 to about 40,000.
European Patent Application Publication No. 0 193 917 discloses a biologically active composition for slow release characterized by a water solution of a complex between a protein and a carbohydrate.
Australian Patent Application No. AU-A-30771/89 discloses stabilization of growth hormone using glycine and mannitol.
U.S. Pat. No. 5,096,885 (which is not prior art) discloses a formulation of hGH for lyophilization containing glycine, mannitol, a non-ionic surfactant, and a buffer. The instant invention provides an unexpectedly stabilized aqueous formulation in the absence of glycine.
hGH undergoes several degradative pathways, especially deamidation, aggregation, clipping of the peptide backbone, and oxidation of methionine residues. Many of these reactions can be slowed significantly by removal of water from the protein. However, the development of an aqueous formulation for hGH has the advantages of eliminating reconstitution errors, thereby increasing dosing accuracy, as well as simplifying the use of the product clinically, thereby increasing patient compliance. Thus, it is an objective of this invention to provide an aqueous hGH formulation which provides acceptable control of degradation products, is stable to vigorous agitation (which induces aggregation), and is resistant to microbial contamination (which allows multiple use packaging).
SUMMARY OF THE INVENTION
One aspect of the invention is a stable, pharmaceutically acceptable, aqueous formulation of human growth hormone comprising human growth hormone,
REFERENCES:
patent: 3928137 (1975-12-01), Monte et al.
patent: 4297344 (1981-10-01), Schwinn et al.
patent: 4357310 (1982-11-01), Chan et al.
patent: 4623717 (1986-11-01), Fernandes et al.
patent: 4783441 (1988-11-01), Thurow
patent: 4812557 (1989-03-01), Yasushi et al.
patent: 4816568 (1989-03-01), Hamilton, Jr. et al.
patent: 4857506 (1989-08-01), Tyle
patent: 4917685 (1990-04-01), Viswanathan et al.
patent: 5008244 (1991-04-01), Miller et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5182258 (1993-01-01), Chiou
patent: 5317012 (1994-05-01), Kudsk
patent: 5374620 (1994-12-01), Clark et al.
patent: 5567677 (1996-10-01), Castensson et al.
patent: 5597802 (1997-01-01), Clark et al.
Skottner et al., "Growth Responses in a Mutant Dwarf Rat to Human Growth Hormone and Recombinant Human Insulin-Like Growth Factor I" Endocrinology 124 (5): 2519-2526 (1989).
Becker, et al., Biotechnology & Applied Biochemistry 9:478-487 (1987).
Pearlman, et al., Current Communications in Molecular Biology, eds. D. Marshak, D. Liu, pp. 23-30 (1989).
Physician's Desk Reference, Medical Economics Co., Orawell, NJ pp. 1193-1194 (1988).
Physician's Desk Reference, Medical Economics Co., Orawell, NJ pp. 1049-1050 (1992).
Physician's Desk Reference, Medical Economics Co., Orawell, NJ pp. 1266-1267 (1992).
The Merck Index, Merck & Co. Inc., Rahway, NJ p. 983, entry No. 7342 (1976).
The Merck Index, Merck & Co. Inc., Rahway, NJ p. 1203, entry No. 7537 (1989).
Merck Manual, Eleventh Ed., Merck & Co., 1989, pp. 1203-1207.
O'Connor Barbara H.
Oeswein James Q.
Genentech Inc.
Hutzell Paula K.
Marschang Diane L.
Prickril Benet
LandOfFree
Human growth hormone aqueous formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human growth hormone aqueous formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human growth hormone aqueous formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2199105